Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BCellMax Life 〉DNA Genetic Cancer Risk Test

DNA Genetic Cancer Risk Test

DNA Genetic Cancer Risk Test

1.Simple blood/saliva test
2.Fully validated performance across all important variant types
3.Best in class accuracy for cancer genetic risk testing
4.Covers genetics risk of most major cancers
5.Innovative, advanced genetic technology for cancer
6.Rigorous classification backed by expert resources

Request for Collaboration
About the SMSEQ® Platform and CellMax-DNA Genetic Cancer Test
CellMax Life's SMSEQ® platform has an analytical specificity of ≥99.999%. This patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and comprehensive genetic cancer risk test, utilizing an expanded 98 gene panel using personal DNA from a saliva or blood sample.

CellMax Life's DNA test uses next generation sequencing to detect gene mutations known to increase lifetime cancer risk. The test surveys for increased risk of 25 cancers including some of the most common cancers: Colon, Lung, Breast, and Oral, along with Prostate, Stomach, along with Prostate, Stomach, Bladder, Thyroid, Ovary and others.
As an example of the extensive breadth gene panel analyzed by CellMax Life: to assess breast cancer risk, the CellMax-DNA test not only covers BRCA1 and BRCA2 genes entirely, but also examines a number of other genes associated with breast cancer including ATM, BARD1, CDH1, CHEK2, NBN, NF1, PALB2, PPM1D, PTEN, RAD51C, RAD51D, STK11, TP53.

Genetic Mutations Can Increase Cancer risk by 20 times

Genetic mutations associated with increased cancer risk are passed from parent to offspring. These inherited abnormal genes are in contrast to acquired mutations which occur after birth and over time, and include environmental factors and lifestyle choices such as smoking or sun exposure.
Individuals with certain inherited genetic mutations carry a higher lifetime risk for various cancers. Their risk of getting these cancers can be up to 20 times greater than individuals without these mutations. Cancers impacted by these inherited gene mutations are typically referred to as hereditary cancers.

“Early cancer detection is the most effective way to fight cancer,” said Dr. Tai Cheng-Jeng, MD, PhD, Chief, Division of Hematology & Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taiwan. “CellMax Life's convenient genetic cancer saliva DNA test based on the next generation sequencing SMSEQ platform offers the broadest gene panel for known hereditary cancers, allowing doctors and their patients to collaborate on personalized, optimal health planning.”

Cancer Risk Identification Enables Personalized Screening for More Effective Medicine
According to the U.S. National Cancer Institute, more than 4 in 10 people in the United States will get cancer in their lifetime. Individuals who inherit mutated genes associated with cancer:
  • Have a greater risk of getting cancer
  • Tend to get their cancers earlier in life
  • The cancer is usually more aggressive
Thus, individuals who know they have inherited an increased cancer risk can work with their doctors to plan for earlier and more frequent cancer screening.
It is well-accepted that the prognosis for cancer survival is higher when detected at early stages. The survival outlook is assessed by the 5-year survival rate stratified based on stage of detection. Some examples are shown below.
  • Colorectal cancer: Stage one has more than 90% survival rate, while stage three and four detection survival is as low as 10%.
  • Breast cancer: Stage one has almost a 100% survival rate. Stage four cancer has only 22%.
The ability for doctors to tailor this screening to individuals with higher risk allows for more efficient and effective medicine.
“Our goal is to make personalized, comprehensive cancer diagnostics affordable and accessible to every individual,” said Dr. Mana K Javey, MD, PhD, VP of Medical Affairs, CellMax Life. “By providing the industry's broadest gene panel for hereditary cancer risk testing, we are enabling individuals and their physicians to do high-impact health planning.”
Case Study: 32-year-old Learns of Hereditary Cancer Risk

Mr. Chen, 32-year-old resident of Kaohsiung, has a family history of cancer, which concerned him for many years. Mr. Chen took the CellMax-DNA Genetic Cancer Risk Test, and learned that he carried a genetic mutation associated with an increased risk of cancer. 

“My family has a history of cancer, but no one had ever been tested for genetic cancer risk -- so I had been worried for many years. When I learned I could find out whether I personally had an increased risk for hereditary cancers through a saliva test, I decided to take it,” said Mr. Chen.
He continued: “I found out that I do carry a genetic mutation related to increased risk of colorectal cancer. Knowing this I will begin screening earlier, and do it more frequently that I would have otherwise.”

  • If you have family cancer history, you are the most recommeded to take the test.
  • You can know your genetic risk of cancer before cancer happens
  • See if you are at risk to pass certain cancer to your children
  • You can manage your genetic risk of cancer with your personalized health management plan, and be proactive about prevention and screening
  • You can understand ways to prevent some external risk in case your test result is positive. (ie. Environment, habits…etc)
Collaboration Options
Marketing & Distribution

More Information
People who like this also like
  • Lipo-Dox®Lipo-Dox®
  • Atopic dermatitis genetic screeningAtopic dermatitis genetic screening
  • “EpiGene” Nucleic Acid Extraction Kit(Non-Sterile)“EpiGene” Nucleic Acid Extraction Kit(Non-Sterile)
  • Surgical InstrumentsSurgical Instruments
  • Synovial Fluid SupplementSynovial Fluid Supplement
  • SpirulinaSpirulina
  • Other APIsOther APIs
  • BR-ViewerBR-Viewer
  • Hereditary Risk EvaluationHereditary Risk Evaluation
  • Phytosensulin® tablePhytosensulin® table